Otherwise, they complete 4–6 courses of consolidation and are then offered maintenance therapy with azacitidine and venetoclax for 2+years, with or without the addition of targeted inhibitors (e.g., FLT3 inhibitors if FLT3-mutated AML; IDH inhibitors if IDH-mutated AML). This evidence concerns the gene IDH2 and acute myeloid leukemia.